Michael Cherny
Stock Analyst at Leerink Partners
(4.36)
# 357
Out of 5,136 analysts
112
Total ratings
61.63%
Success rate
14.88%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Initiates: Outperform | $48 | $43.41 | +10.57% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $9.32 | +39.48% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $186.77 | +12.44% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $834.16 | +1.90% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $213.56 | -12.91% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $26.12 | +7.20% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.26 | +138.10% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $24.20 | -4.96% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $616.45 | -46.47% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $31.32 | +27.71% | 10 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $55 → $75 | $79.33 | -5.46% | 11 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $40.27 | +123.49% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $169.23 | +65.46% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $76.28 | +10.12% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $241.35 | +2.76% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $184.77 | +38.01% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.35 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $349.93 | -21.41% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $262.00 | -0.76% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.75 | +190.91% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $6.61 | +157.19% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $2.27 | +2,212.78% | 2 | Jan 5, 2022 |
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $43.41
Upside: +10.57%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $9.32
Upside: +39.48%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $186.77
Upside: +12.44%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $834.16
Upside: +1.90%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $213.56
Upside: -12.91%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $26.12
Upside: +7.20%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.26
Upside: +138.10%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $24.20
Upside: -4.96%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $616.45
Upside: -46.47%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $31.32
Upside: +27.71%
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $79.33
Upside: -5.46%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $40.27
Upside: +123.49%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $169.23
Upside: +65.46%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $76.28
Upside: +10.12%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $241.35
Upside: +2.76%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $184.77
Upside: +38.01%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.35
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $349.93
Upside: -21.41%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $262.00
Upside: -0.76%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.75
Upside: +190.91%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $6.61
Upside: +157.19%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $2.27
Upside: +2,212.78%